Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 17/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23835494 | 1.00 | ACE (0.71) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL9068520 | 0.88 | ACE (0.56) | ACE | |
| SCHEMBL8726316 | 0.86 | ACE (0.55) | ACE | |
| SCHEMBL9068766 | 0.86 | ACE (0.55) | ACE | |
| SCHEMBL17277128 | 0.86 | ACE (0.65) | ACEKDM4EMAPTTHRBALOX15 | |
| SCHEMBL9068565 | 0.86 | ALDH1A1 (0.58) | ACEMAPT | |
| SCHEMBL9068566 | 0.86 | ALDH1A1 (0.58) | ACEMAPT | |
| SCHEMBL929011 | 0.86 | ACE (0.55) | ACE | |
| SCHEMBL929013 | 0.86 | ACE (0.55) | ACE | |
| SCHEMBL9068730 | 0.86 | ACE (0.55) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875268-B2 | The use of certain dimercaptoamides as reducing agents, 2-mercapto-N-(2-mercaptoethyl)acetamide, results in curling that is satisfactoryin terms of intensity and in terms of hold over time; less substantial degradation of the hair fiber compared with the reducing agents of the prior art; permanent waves | L'OREAL S.A. (FR) | 2011-01-25 | — | — | US | claimed |
| EP-1584615-B1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | OREAL (FR) | 2008-05-28 | — | — | EP | claimed |
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | L'OREAL S.A. (FR) | 2006-01-19 | — | — | US | claimed |
| EP-1584615-A1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | L'OREAL (FR) | 2005-10-12 | — | — | EP | claimed |
| WO-2025019927-A1 | COMPOSITIONS, METHODS AND USES OF BUCILLAMINE IN THE TREATMENT A VICTIM EXPOSED TO A CHEMICAL WARFARE AGENT | REVIVE THERAPEUTICS LTD (CA) | 2025-01-30 | — | — | WO | disclosed |
| WO-2023184031-A1 | METHOD AND USE OF BUCILLAMINE IN THE PREVENTION AND TREATMENT OF STROKE | REVIVE THERAPEUTICS LTD (CA) | 2023-10-05 | — | — | WO | disclosed |
| US-20230172884-A1 | USE OF BUCILLAMINE IN THE TREATMENT OF INFECTIOUS DISEASES | REVIVE THERAPEUTICS LTD (CA) | 2023-06-08 | — | — | US | disclosed |
| EP-4121035-A1 | USE OF BUCILLAMINE IN THE TREATMENT OF INFECTIOUS DISEASES | Revive Therapeutics Ltd. (CA) | 2023-01-25 | — | — | EP | disclosed |
| WO-2021184115-A1 | USE OF BUCILLAMINE IN THE TREATMENT OF INFECTIOUS DISEASES | REVIVE THERAPEUTICS LTD. (CA) | 2021-09-23 | — | — | WO | disclosed |
| US-7875268-B2 | The use of certain dimercaptoamides as reducing agents, 2-mercapto-N-(2-mercaptoethyl)acetamide, results in curling that is satisfactoryin terms of intensity and in terms of hold over time; less substantial degradation of the hair fiber compared with the reducing agents of the prior art; permanent waves | L'OREAL S.A. (FR) | 2011-01-25 | — | — | US | disclosed |
| EP-1584615-B1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | OREAL (FR) | 2008-05-28 | — | — | EP | disclosed |
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | L'OREAL S.A. (FR) | 2006-01-19 | — | — | US | disclosed |
| EP-1584615-A1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | L'OREAL (FR) | 2005-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | KRT18, CKAP4, S100A4 | ACE 3872/4885KDM4E 488/4885MAPT 998/4885 |
| US-20230172884-A1 | USE OF BUCILLAMINE IN THE TREATMENT OF INFECTIOUS DISEASES | ACE, NEU1, NEU3 | ACE 1/4885KDM4E 4484/4885MAPT 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.